Welcome to our dedicated page for Guardant Health news (Ticker: GH), a resource for investors and traders seeking the latest updates and insights on Guardant Health stock.
Guardant Health, Inc. develops precision oncology diagnostics and data products centered on blood and tissue testing for cancer care. Company news commonly covers the Guardant360 liquid biopsy and Guardant360 Tissue franchises, Guardant Reveal for molecular residual disease monitoring, Shield colorectal cancer screening, and InfinityAI real-world data and analytics.
Recurring updates include financial results across Oncology, Screening, and Biopharma & Data revenue categories; FDA companion diagnostic approvals for Guardant360 CDx; research presentations in tumor typing, therapy selection, methylation and multiomic testing; and biopharma collaborations that use Guardant tissue and liquid biopsy assays to support targeted therapy development.
Guardant Health (Nasdaq: GH) announced the approval of equity awards for new non-executive employees under its 2023 Employment Inducement Incentive Award Plan. The compensation package includes:
- 110,681 restricted stock units (RSUs) granted to 102 new non-executive employees
- One non-qualified stock option award to purchase 22,091 shares granted to one new employee
The stock options have an exercise price of $42.44 per share, matching Guardant's closing price on Nasdaq on February 24, 2025. The RSUs vest annually over three years, while stock options vest one-third after one year and monthly thereafter over 24 months, subject to continued employment. These grants were approved on February 11, 2025, with a grant date of February 24, 2025, in accordance with Nasdaq Listing Rule 5635(c)(4).
Guardant Health (Nasdaq: GH) released its second annual 'Closing the Gap: CRC Screening Insights' survey, revealing significant barriers to colorectal cancer (CRC) screening. The Harris Poll survey of 1,000 adults aged 45-84 and 350 physicians showed that patient fear and anxiety are increasing barriers to screening, with 29% of patients reporting these concerns, up from 22% in 2024.
Key findings include that 93% of primary care providers believe patients are less likely to avoid screening if offered an FDA-approved blood test option. The survey highlighted that over 50 million Americans are not up-to-date with CRC screening, with People of Color showing lower screening rates (63%) compared to white people (72%).
Guardant Health's Shield blood test, recently FDA-approved as a primary CRC screening option, offers a more convenient alternative to traditional methods. The test requires no preparation or invasive procedures and can be completed during routine healthcare visits. 92% of Americans indicated they would be more satisfied with their wellness visit if offered this blood test option and more likely to get a colonoscopy following a positive blood test result.
Guardant Health (GH) reported strong financial results for Q4 and full year 2024, with total revenue reaching $739.0 million, up 31% year-over-year. The company's Q4 revenue was $201.8 million, a 30% increase from the previous year.
Key performance highlights include:
- Clinical oncology volume grew 24% in Q4, with approximately 57,300 tests
- Shield screening program reported 6,400 tests in Q4 with $4.1 million revenue
- Improved free cash flow burn to $275 million in 2024 from $345 million in 2023
For 2025, Guardant Health expects:
- Revenue between $850-860 million (15-16% growth)
- Oncology clinical volume growth of approximately 25%
- Shield screening revenue of $25-30 million
- Free cash flow burn improvement to $225-235 million
Guardant Health (Nasdaq: GH), a precision oncology company, has announced its participation in four major upcoming investor conferences. The company will attend the BTIG 12th Annual MedTech, Digital Health, Life Science & Diagnostic Tools Conference in Snowbird, UT, hosting one-on-one meetings on February 11th-12th.
Additionally, Guardant Health will participate in three March conferences: the TD Cowen 45th Annual Health Care Conference in Boston (March 4th, 10:30 AM ET), the Leerink Partners Global Health Conference in Miami (March 11th, 4:20 PM ET), and the Barclays 27th Annual Global Healthcare Conference in Miami Beach (March 12th, 1:30 PM ET).
Interested investors can access live and archived webcasts of these sessions through the Investors section of Guardant Health's website.
Guardant Health (Nasdaq: GH) announced a debt exchange transaction on February 6, 2025, where it will issue $600 million of 1.25% Convertible Senior Notes due 2031 in exchange for retiring approximately $659.3 million of its outstanding 0% Convertible Senior Notes due 2027.
The new notes will have an initial conversion rate of 16.0716 shares per $1,000 principal amount, representing a conversion price of $62.22 per share with a 35% premium. After the transaction closes around February 14, 2025, approximately $490.7 million of 2027 Notes will remain outstanding.
Additionally, Guardant Health plans to repurchase approximately $45 million of its common stock, while the exchange agent intends to purchase approximately $35 million of shares from transaction participants.
Guardant Health (Nasdaq: GH), a precision oncology company, has announced it will release its fourth quarter and full year 2024 financial results after market close on Thursday, February 20, 2025. The company will host a conference call and webcast at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time on the same day to discuss the results. Investors can access the live audio webcast through the company's website, and a replay will be available after the event.
Guardant Health (Nasdaq: GH) has partnered with the Abu Dhabi Public Health Center to implement a non-invasive blood-based colorectal cancer screening program using their Shield™ test. The agreement, established through Hikma Pharmaceuticals PLC, will be managed by the M42 healthcare system.
The initiative aims to address the significant challenge of colorectal cancer in Abu Dhabi, where it ranks as the third most common cancer type, with 63% of cases diagnosed at late stages. The Shield test will be integrated into the ADPHC's IFHAS comprehensive health screening program, available across major healthcare facilities in Abu Dhabi, Al Ain, and the Al Dhafra region.
The program targets to screen approximately 10,000 people in its first year, offering a more comfortable screening alternative to increase participation rates and improve early detection outcomes.
Guardant Health (Nasdaq: GH) announced its participation in the ASCO Gastrointestinal Cancers Symposium (ASCO GI) in San Francisco, January 23-25, 2025, where it will present significant data on its precision oncology tools. The presentations will focus on cancer screening, recurrence monitoring, treatment selection, and therapy development.
A key highlight includes data from the phase II NEO trial demonstrating Guardant Reveal's potential as a decision tool for organ preservation in node-negative rectal cancer patients. The company will present multiple studies across its product portfolio, including Guardant360, GuardantINFORM, and Shield, covering topics such as colorectal cancer screening cost-effectiveness, genomic landscapes in various cancers, and real-world survival differences in biliary tract cancer patients.
According to Dr. Craig Eagle, Guardant Health's chief medical officer, the data supports the growing value of precision oncology tools, particularly liquid biopsy, in GI cancer detection, treatment selection, and monitoring, potentially leading to more personalized cancer care and improved patient outcomes.
Guardant Health (Nasdaq: GH) announced Medicare coverage expansion for its Guardant Reveal test through Palmetto GBA. The coverage now includes surveillance testing for colorectal cancer (CRC) patients following curative intent therapy, expanding from the previous early post-surgical setting coverage.
The Guardant Reveal, running on the Smart Liquid Biopsy platform, is a blood-based test that uses epigenomic analysis to detect circulating tumor DNA (ctDNA) for minimal residual disease (MRD) monitoring. This tissue-free approach addresses the needs of cancer patients without available tissue specimens or those for whom tissue collection is challenging.
Of the 18 million cancer patients in the U.S. who could benefit from MRD testing, less than 3% currently receive it. Over 12 million cancer patients are more than five years post-surgery, making tissue specimen collection difficult, and over three million patients have no tumor tissue available.
Guardant Health (GH) and ConcertAI have announced a collaboration to create the first multi-modal real-world data solution that integrates comprehensive patient electronic medical records with genomic and epigenomic tumor profiling information across cancer care. The partnership combines ConcertAI's database of 5.5M clinical records with Guardant's profiling data across 60+ tumor types.
The integrated platform will provide biopharmaceutical companies access to extensive data including methylation data from Guardant Infinity smart liquid biopsy platform, helping researchers better understand disease biology, identify drivers of tumor evolution, and study resistance mechanisms. The solution covers the entire cancer care spectrum, from monitoring residual disease in early-stage cancer to treatment selection in advanced cases.
This collaboration aims to accelerate cancer therapy research and development by providing unprecedented insights into patient cancer journeys and tumor interactions. Financial terms of the agreement were not disclosed.